The main hypothesis of the HEPACORT study is that upon diagnosis of endogenous Cushing's syndrome, significant liver fibrosis may be present, particularly in the most severe forms of Cushing's syndrome.
the HEPACORT study is the first exploratory study to assess the severity of liver fibrosis in patients with Cushing's syndrome or suspected of presenting by Magnetic Resonance Elastography (MRE).
age ≥ 18 years old;
Person affiliated to a social security scheme or beneficiary of such a scheme;
Person having received complete information on the organization of the research and having signed informed consent;
Person having carried out a preliminary clinical examination adapted to the research.
Person having taken corticosteroid therapy for more than 3 months during the 2 years preceding inclusion;
Person having received corticosteroid therapy of shorter duration with discontinuation less than one month before inclusion;
Person having taken anticortisolic treatment for more than 3 months during the 2 years preceding inclusion;
Person with chronic liver disease;
Parallel
Magnetic resonance elastography (MRE)
DeviceMagnetic Resonance Imaging (MRI) imaging with low-frequency vibrations to create a visual map (elastogram) that shows stiffness of body tissues
Estimation of the severity of hepatic fibrosis by MRE (kPa).
Estimation of the severity of hepatic fibrosis in kPa by a non-invasive elastography method : magnetic resonance elastography.
Evaluation of the presence of hepatic fibrosis by MRE (kPa).
Evaluation of the presence of hepatic fibrosis by ERM : ERM value ≥ 72.5 kPa.
Evaluation of the association between hyperglycemia (blood glucose by g/L) with the presence of Fibrosis by MRE (kPa).
Evaluation of the association between high blood pressure (mmHg) with the presence of Fibrosis by MRE (kPa).
Evaluation of the association between overweight (kg) with the presence of Fibrosis by MRE (kPa).
Click on the lead sponsor to view all of their trials.
